Revolutionize Precision Medicine

We unravel disease mechanisms
by identifying aberrant activities
of cell signaling pathways

news

InnoSIGN appoints Eric Lindquist new Chief Executive Officer

news

InnoSIGN starts offering OncoSIGNal pathway profiling services for clinical use in the US

events

Identifying mutation-independent signaling pathway activation in molecular subtypes of triple negative breast cancers

events

Racial differences in estrogen receptor signaling pathway activity in breast cancer patients